FocusAutoimmune Disease

Autoantibodies: Double Agents in Human Disease

See allHide authors and affiliations

Science Translational Medicine  22 May 2013:
Vol. 5, Issue 186, pp. 186fs19
DOI: 10.1126/scitranslmed.3006288

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Abstract

Binding of cross-reactive autoantibodies to peptidylarginine deiminase 4 (PAD4) increases its activity by lowering its requirement for Ca2+, leading to increased production of citrullinated autoantigens and worse outcomes in patients with rheumatoid arthritis (Darrah et al., this issue).

View Full Text